Nantahala Capital Management, LLC Cyma Bay Therapeutics, Inc. Transaction History

Nantahala Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$7.47 - $10.95 $9.24 Million - $13.5 Million	-1,236,796 Reduced 69.09%	553,307 $6.06 Million
Q1 2023 May 15, 2023	SELL	$5.88 - $9.59 $2.71 Million - $4.42 Million	-460,456 Reduced 20.46%	1,790,103 $15.6 Million
Q4 2022 Feb 14, 2023	SELL	$3.22 - $6.27 $721,602 - $1.41 Million	-224,100 Reduced 9.06%	2,250,559 $14.1 Million
Q3 2022 Nov 10, 2022	SELL	$2.77 - $4.25 $469,922 - $720,999	-169,647 Reduced 6.42%	2,474,659 $8.66 Million
Q2 2022 Aug 15, 2022	BUY	$1.72 - $3.39 $1.29 Million - $2.54 Million	750,309 Added 39.62%	2,644,306 $7.8 Million
Q1 2022 May 13, 2022	SELL	$2.77 - $3.64 $294,021 - $386,367	-106,145 Reduced 5.31%	1,893,997 $5.89 Million
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $6.46 Million - $9.2 Million	2,000,142 New	2,000,142 $6.76 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nantahala Capital Management, LLC with notifications on news.